Close

Mylan Pharma rolls out generic benign prostatic hyperplasia drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...
- Advertisement -

Mylan Pharmaceuticals has introduced Alfuzosin Hydrochloride Extended-release Tablets, 10mg.Mylan’s Alfuzosin Hydrochloride Extended-release Tablets, 10mg are generic equivalent to Uroxatral, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Uroxatral belongs to a group of drugs called alpha-adrenergic blockers.Uroxatral relaxes the muscles in the prostate and bladder neck, making it easier to urinate.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...

5 Functional Medicine Clinics in Denver for a Personalized Approach to Chronic Inflammation

Chronic inflammation underlies a surprisingly wide range of diagnoses:...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »